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ORIGINAL ARTICLE
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ABSTRACT
Background: Clinical nodal (cN) staging is a key element in treatment decisions in patients with
esophageal cancer (EC). The reliability of cN status regarding the effect on response and survival after
neoadjuvant chemoradiotherapy (nCRT) with esophagectomy was evaluated in determining the up-
and downstaged pathological nodal (pN) status after surgery alone.
Material and methods: From a prospective database, we included all 395 EC patients who had sur-
gery with curative intent with or without nCRT between 2000 and 2015. All patients were staged by a
standard pretreatment protocol: 16-64 mdCT, 18 F-FDG-PET or 18 F-FDG-PET/CT and EUS±FNA. After
propensity score matching on baseline clinical tumor and nodal (cT/N) stage and histopathology, a
surgery-alone and nCRT group (each N¼ 135) were formed. Clinical and pathological N stage was
scored as equal (cN¼pN), downstaged (cN>pN) or upstaged (cN<pN). Prognostic impact on disease
free survival (DFS) was assessed with multivariable Cox regression analysis (factors with p value <.1 on
univariable analysis).
Results: The surgery-alone and nCRT group did not differ in cT/N status. Pathologic examination
revealed equal staging (32 vs. 27%), nodal up (43 vs. 16%) and downstaging (25 vs. 56%), respectively
(p< .001). Nodal up-staging was common in cT3-4a tumors and adenocarcinomas in the surgery-alone
group, while nodal downstaging was found in half of cT1-2 and cT3-4 regardless of tumortype after
nCRT. Prognostic factors for DFS were pN (p¼ .002) and lymph-angioinvasion (p¼ .016) in surgery-
alone, and upper abdominal cN metastases (p¼ .012) and lymph node ratio (p¼ .034) in the
nCRT group.
Conclusions: Despite modern staging methods, correct cN staging remains difficult in EC. Nodal over-
staging (cN>pN) occurred more often than understaging impeding an adequate assessment of patho-
logic complete response and prognosis after nCRT.
SYNOPSIS
Preoperative assessment of true nodal response after nCRT in EC remains difficult with clinical nodal
upstaging (16% vs. 43%) and downstaging (56% vs. 25%) after nCRT and surgery alone, respectively.
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Introduction
Accurate staging of lymph nodes (LNs) is crucial in treatment
decision making, prediction of true response to neoadjuvant
chemoradiotherapy (nCRT) and prognosis in patients with
esophageal cancer (EC) [1–4]. Clinical nodal (cN) staging
commonly consists of computed tomography (CT), 18-F-
fluorodeoxyglucose positron emission tomography (18F-FDG-
PET) or integrated PET-CT and endoscopic ultrasonography
(EUS) with fine needle aspiration (FNA) [5,6]. The reliability of
cN staging is shown at pathologic examination in EC patients
after surgery alone, and may proceed after nCRT [5–12].
While pathological nodal (pN) status is a strong prognostic
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factor, the impact of nCRT to the veracity of the N status is
poorly studied [10].
In patients with EC, nodal downstaging after nCRT
(cN> ypN stage) is described in 45–69% [10,13]. Besides
pathologic complete response (pCR), pN status, both after
nCRT (ypN) as after surgery alone (pN), is one of the most
important prognostic factors in EC [2,3,10,14]. However, a
substantial part of nodal downstaging is associated with
overestimation of cN involvement, as reported in 30–63%
after surgery alone [6,9,15]. This implicates an overestimation
of nodal response, as pathologic negative nodes after nCRT
(ypN0) include both true node negative (cN0¼ ypN0) and
sterilized nodes (cNþ to ypN0). On the other hand, falsely
assessed clinical node negativity (cN0¼pNþ) might withhold
patients from nCRT or adequate radiotherapy dosage on true
metastatic LNs.
Furthermore, the impact of locations of LN metastases on
survival remains unclear. LN metastases on both diaphrag-
matic sides had a detrimental effect on survival after surgery
alone, although others failed to prove prognostic impact of
localization after nCRT [3,13].
The aim of this study was to evaluate the impact of the
reliability of cN status after primary surgery and the pre-
sumed effect on pCR to nCRT in a propensity matched group
of EC patients, in determining the discordance between clin-
ical and pN staging in both groups. In addition, we deter-




Data were collected from a prospectively managed database
of 419 consecutive patients with locally advanced EC (cT2-
4aN0-3M0 or cT1N1-3M0) who underwent an esophagectomy
with curative intent between 2000 and 2015.
From 2004 to 2009, nCRT was given in the randomized
controlled ChemoRadiotherapy for Esophageal Cancer fol-
lowed by Surgery Study (CROSS trial). From 2009 onwards,
the same nCRT regimen was given as standard treatment in
all patients with locally advanced EC [1,16]. Excluded were
patients with concurrent malignancies (N¼ 5), missing data
(N¼ 12), salvage surgery or preceding endoscopic mucosal
resection (N¼ 7). Of the remaining 395 patients, 222 under-
went surgery alone and 173 nCRT plus surgery (Table S1).
After propensity score matching on clinical T stage (cT), N
stage (cN), and histopathologic tumor type, both groups con-
sisted of 135 patients. This study was performed according
to the National Health Care guidelines with approval of our
Institutional Ethical Board.
Clinical staging
During the whole study period, the preoperative workup in
all patients consisted of 16–64 multidetector CT thorax-abdo-
men (2mm slices) and 18 F-FDG-PET or FDG-PET/CT followed
by EUS with FNA of suspected LN’s on EUS and/or PET/PET-
CT. EUS was commonly performed after PET/PET-CT for the
best possible FNA-guidance by two experienced GI-endo-
scopists in our high-volume institute, according to the 7th
TNM/AJCC system [17–20]. LN involvement was considered
clinical positive (cNþ) if highly suspected (1cm on short
axis on PET/CT and/or correlated with cortical thickening and
increased FDG-uptake), or on EUS by size, shape, echoic pat-
tern, and border sharpness. FNA was performed in suspected
LNs when relevant in determining the extent of radiation
fields and/or nodal dissection. LNs were negative if a repre-
sentative FNA was without tumor cells, as described earlier
[19,20]. To prevent false positivity, nodal FNA was not per-
formed if the needle had to pass the primary tumor.
Before 2009, a FDG-PET scan was followed after CT
(N¼ 145; 53.7%). After 2009 patients underwent an inte-
grated FDG-PET/CT scan (N¼ 125; 46.3%). EUS was per-
formed with (N¼ 48;17.8%) or without FNA (N¼ 222;82.2%).
Endobronchoscopic ultrasonography (EBUS) with FNA was
performed in suspected high paratracheal level 2 LNs (N¼ 5;
1.9%). Staging of all patients was also discussed in a multi-
disciplinary gastro-esophageal tumor board.
Treatment and pathology
All patients underwent a transthoracic open or minimally
invasive esophagectomy with standard 2-field dissection of
mediastinal, para-esophageal, and upper abdominal (along
splenic, common hepatic, celiac artery) LNs, and high
paratracheal LNs (station 2) when indicated [21,22].
Neoadjuvant CRT consisted of carboplatin (area under curve
of 2mg/ml/min) and paclitaxel (50mg/m2 body surface) with
concurrent radiotherapy of 41.4 Gy (23 fractions of 1.8 Gy) for
5weeks, followed by surgical resection within 6–10weeks
[16]. Pathologic examination of the resection specimen was
performed according to a standard institutional protocol by
two experienced upper-GI pathologists [23]. Tumor response
was scored at microscopic level using the Mandard tumor
regression grading (TRG) system from pCR (ypT0N0; TRG 1)
to absence of regressive changes (TRG 5) [24]. The presence
of viable tumor cells within LNs was considered as nodal
involvement (ypNþ).
Clinical versus pN staging
cN staging was compared with pathological staging and
scored equal stage (cN¼pN) in either node negative
(cN0¼ pN0) and node positive (cN1-3¼pN1-3), and as nodal
downstaging (cN>pN), or upstaging (cN< pN). Accuracy,
sensitivity, specificity, positive and negative predictive value
of cN staging, in which correct dichotomous nodal staging
was defined as true node negative [cN0¼ pN0] or true node
positive [cNþ¼ pNþ; regardless of stage]), were calculated
in the surgery-alone group. We did not perform this in the
nCRT group, because the analyses after nCRT are biased by
the potential sterilizing nodal downstaging effect. Therefore,
we intended to assess the nodal downstaging effect of nCRT
by comparing nodal downstaging after nCRT with the
changed nodal status at pathologic examination after surgery
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alone. Nodal downstaging from cNþ to ypN0 can only be
considered as potential sterilized effect of nCRT (true treat-
ment response), but this may lead to a false treatment
response in the true cN0 group (cN0¼ ypN0), which is par-
tially based on incorrect assessment. This concept of nodal
misstaging based on up- and downstaging is also influenced
by histologic type and clinical T stage [25].
Site-specific LN metastases and prognostic value
LN regions were marked prospectively according to a stand-
ard pathologic protocol, including the AJCC node mapping
[17,22]. We determined the effect of nodal up-/downstaging
in patients adequately by recording clinically suspected node
locations, if known (surgery-alone: N¼ 124; nCRT: N¼ 122)
and the prognostic value of these locations on DFS. LNs
were scored in 3 regions: upper mediastinal (paratracheal/
para-aortic; station 2–6), lower mediastinal (para-esophageal/
subcarinal/pulmonary ligament: station 7–9 and 15), and
upper abdominal (station 16-20) (Figure 1).
Follow-up
Patients were followed at 4weeks postoperatively and every 3,
4 and 6months during the first, second and third year, respect-
ively, and yearly thereafter. Recurrences were detected with
radiological imaging (CT or PET/CT), endoscopy and/or histo/
cytologic examination. DFS was measured from the date of
treatment until recurrence or end of follow-up.
Statistical analysis
Patient and tumor characteristics, and details on HER2 test-
ing were displayed with counts and percentages, means and
standard deviations (SDs), or medians and interquartile
ranges (IQRs). Chi-square tests and likelihood ratios were
used to determine differences in LN involvement and loca-
tion. Potential prognostic factors in the univariable analyses,
including clinical and pathological upper/lower mediastinal
and upper abdominal LNs, and the variable nodal up- and
downstaging, with p value <.10 on univariable regression
analysis were included in a multivariable Cox regression ana-
lysis for DFS. p value <.05 was regarded as statistically





Upper      
abdominal 
cN+: n=17 (13.7%)          
pN+: n=7 (5.6%)
cN+: n=69 (55.6%) 
pN+: n=65 (52.4%)
cN+: n=37 (29.8%) 
pN+: n=62 (50.0%)
nCRT group (n=122) 
cN+: n=21 (17.2%) 
pN+: n=0 (0.0%)
cN+: n=65 (53.3%) 
pN+: n=20 (16.4%)
cN+: n=40 (32.8%) 
pN+: n=20 (16.4%)
N=: n=104 (83.9%) 
N↑: n=5 (4.0%) 
N↓: n=15 (12.1%)
N=: n=72 (58.1%) 
N↑: n=24 (19.4%) 
N↓: n=28 (22.6%)
N=: n=101 (82.8%) 
N↑: n=0 (0.0%)    
N↓: n=21 (17.2%)
N=: n=55 (45.1%) 
N↑: n=11 (9.0%)   
N↓: n=56 (45.9%)
N=: n=74 (60.7%) 
N↑: n=14 (11.5%) 
N↓: n=34 (27.9%)
N=: n=79 (63.7%) 
N↑: n=35 (28.2%) 
N↓: n=10 (8.1%)
cN0=pN0/cN+=pN+ Sensitivity Specificity PPV NPV Accuracy
Overall 78.6% 40.5% 77.8% 41.7% 68.1%
Upper mediastinal 28.6% 87.2% 11.8% 95.3% 83.9%
Lower mediastinal 63.1% 52.5% 59.4% 56.4% 58.1%
Upper abdominal 43.6% 83.9% 73.0% 59.8% 63.7%
  
Figure 1. Distribution of clinical and pathological lymph node involvement in the surgery-alone and nCRT group. Comparison of clinical and pathological nodal
staging in the surgery-alone and neoadjuvant chemoradiotherapy groups, displayed per lymph node location. Accuracy, sensitivity, specificity, positive and negative
predictive value of cN staging (correct nodal negative [cN0¼ pN0] or correct nodal positive cNþ¼ pNþ]) is calculated in the surgery-alone group. True positive
(TP), false positive (FP), true negative (TN), and false negative (FN) clinical node stage were used to determine overall accuracy ((TPþ TN)/(TPþ FPþ FNþ TN)) of
correct dichotomous (positive vs. negative) nodal staging (cN0¼ pN0 and cNþ¼ pNþ, regardless of which cNþ/pNþ stage), as well as sensitivity (TP/(TPþ FN)),
specificity (TN/(TNþ FP)), positive predictive value (PPV: TP/(TPþ FP)), and negative predictive value (NPV: TN/(TNþ FN)). The nodal downstaging effect due to
neoadjuvant chemoradiotherapy is expressed by the lower proportion of patients with pNþ stage in all locations, and by the percentage of patients that had nodal
downstaging in all three locations. nCRT: neoadjuvant chemoradiotherapy; cNþ: clinical node positive; pNþ: pathologic node positive; N=: equal nodal staging;
N": nodal upstaging; N#: nodal downstaging; cN0: clinical node negative; pN0: pathologic node negative PPV: positive predictive value; NPV: negative predict-
ive value.
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significant. DFS in patients with nodal up- and downstaging
in both groups was displayed with Kaplan–Meier curves and
tested using the log rank test. Statistical analyses were per-
formed with IBM SPSS Statistics for Windows, Version 23.0
(Armonk, NY: IBM Corp.).
Results
Patients and tumor characteristics in the nCRT and
surgery-alone group
Baseline characteristic of all patients can be found in Table
S1. After propensity score matching, the groups did not dif-
fer in cT stage, cN stage and histology, but only in age and
the known effects of nCRT including radicality (R0), patho-
logical T and N stages, lymph-angioinvasion, median number
of positive resected LNs, and the ratio of positive/all
retrieved LNs (LN ratio >0.2), as well as period of resection
(Table 1). All patients in the nCRT group received full radio-
therapy doses and >75% completed chemotherapy (98%
had 4 cycles). The pathologic complete response (pCR) of
the primary tumor (ypT0) after nCRT was 20.7% (N¼ 28),
while pCR rate including histologically negative nodes
(ypT0N0) was 15.6% (N¼ 21). Higher pCR rates (ypT0N0)
were seen in SCC (36.4 vs. 11.5% in AC; p¼ .007).
Nodal staging: clinical versus pathological N stage and
impact of nCRT
In the surgery-alone group, 21 of the 36 (58.3%) cN0 patients
were upstaged and 22 of the 37 patients with pN0 were
downstaged cNþ patients (59.5%). In the nCRT group, 14 of
36 (38.9%) cN0 patients were upstaged and 70 of 92 ypN0
Table 1. Patient and tumor-related characteristics in the surgery-alone and nCRT group after propensity score matching in EC patients
treated between 2000 and 2015.
Surgery-alone (n¼ 135), no. (%) nCRT (n¼ 135), no. (%) p value
Male 114 (84.4) 106 (78.5) .210a
Age (years), median (IQR) 65 (57–71) 63 (57–68) .013b
Histology .737a
Adenocarcinoma 115 (85.2) 113 (83.7)
Squamous cell carcinoma 20 (14.8) 22 (16.3)
Tumor location .988a
Middle esophagus 13 (9.6) 13 (9.6)
Distal esophagus 96 (71.1) 97 (71.9)
GEJ 26 (19.3) 25 (18.5)
Tumor length (cm), median (IQR) 5 (3–7) 5 (3–7) .786b
cT-stage .527c
T1 3 (2.2) 1 (0.7)
T2 18 (13.3) 21 (15.6)
T3/T4a 114 (84.4) 113 (83.7)
cN-stage .984c
N0 36 (26.7) 36 (26.7)
N1 67 (49.6) 67 (49.6)
N2 28 (20.7) 29 (21.5)
N3 4 (3.0) 3 (2.2)
Period of resection <.001a
2000–2005 62 (45.9) 0 (0.0)
2006–2010 60 (44.4) 31 (23.0)
2011–2015 13 (4.8) 104 (77.0)
pT-stage <.001a
T0 0 (0.0) 28 (20.72)
T1 11 (8.1) 20 (14.8)
T2 27 (20.0) 24 (17.8)
T3/T4 97 (71.8) 63 (46.7)
pN-stage <.001a
N0 37 (27.4) 92 (68.1)
N1 41 (30.4) 29 (21.5)
N2 31 (23.0) 11 (8.1)
N3 26 (19.3) 3 (2.2)
pCR (ypT0N0) – 21 (15.6) –
Adenocarcinoma – 13/113 (11.5)
Squamous cell carcinoma – 8/22 (36.4) .007a

R1-resection 16 (11.9) 7 (5.2) .050a
Perineural growth 40 (29.9) 28 (21.1) .099a
Lymph-angioinvasion 51 (38.3) 29 (21.8) .003a
Number of resected LN, median (IQR) 14 (9–19) 15 (12–22) .009b
Number of positive LN, median (IQR) 2 (2–5) 0 (0–1) <.001b
Lymph node ratio >0.2 60 (44.8) 12 (8.9) <.001a
Postoperative (30-day) mortality 7 (5.2) 2 (1.5) .172d




dFisher’s exact test.Difference in pCR between adenocarcinoma and squamous cell carcinoma.
nCRT: neoadjuvant chemoradiotherapy; IQR: interquartile range; GEJ: gastroesophageal junction, pretreatment staging; cT: clinical tumor
stage; cN: clinical nodal stage; pT: pathological tumor stage; pCR: pathologic complete response; pN: pathological nodal stage; LN: lymph
node; R1: microscopic positive resection margin.
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(76.1%) downstaged cNþ patients. The rate of positive
nodes differed considerably in the nCRT (31.9%) compared
to surgery-alone (72.6%) group, with a remarkable reduction
in (y)pN2-3 stages (from 71.8 to 46.7%; Table 1).
Table 2 depicts nodal up- and downstaging in both
groups, and subdivided for LN locations. In the surgery-alone
group, 43 (31.9%, of whom 15 cN0¼ pN0 and 28 cN1-
3¼ pN1-3) patients were staged adequately. Nodal upstaging
occurred in 58 (43.0%) and downstaging in 34 (25.2%)
patients after primary surgery, whereas the accuracy of cN
detection (cN0¼pN0 or cNþ¼ pNþ) was 68.1% (Figure 1).
Significant differences were seen pertaining the histologic
type, with relatively more upstaging in AC and more down-
staging in SCC (Table 2). Nodal upstaging occurred more
often in cT3/T4a compared to cT1/T2 tumors in the surgery-
alone group (p¼ .002), while nodal downstaging occurred in
one third of the cT1/T2 (N¼ 7; 33.3%) compared with 23.7%
(N¼ 27) of cT3/4a tumors.
In the nCRT group, 38 (28.1%, of whom 22 cN0¼ ypN0
and 16 cN1-3¼ ypN1-3) patients had equal cN/ypN stages
with nodal up- and downstaging in 22 (16.3%) and 75
(55.6%) patients, respectively. Nodal downstaging occurred
in about half of the patients after nCRT in both cT1/T2 and
cT3/T4a, and in more than half of both AC (54.9%) and SCC
(59.1%) tumors. Nodal upstaging occurred in none of SCC
tumors treated with nCRT.
Clinical and pathological location of LN metastases
Figure 1 displays the distribution of cNþ and pNþ per LN
location. In the surgery-alone group, the sensitivity in
detecting low mediastinal LN metastases (63.1%) was higher
than in the upper abdominal (43.6%) and upper mediastinal
(28.6%) stations. The specificity was high in upper medias-
tinal (87.2%) and abdominal (83.4%) LNs, and lower in lower
mediastinal nodes (52.5%; Figure 1).
After nCRT, no upper mediastinal LN metastases were
detected. Upstaging occurred often in upper abdominal LNs
in the surgery-alone group, while downstaging frequently
occurred in lower mediastinal nodes (45.9%).
Nodal up-, down- and correct staging differed significantly
in upper mediastinal, lower mediastinal and upper abdom-
inal LNs between the surgery-alone and nCRT groups
(p¼ .022, p< .001, and p< .001, respectively; Table 2).
Nodal up-/downstaging, LN locations and disease-
free survival
Five-year DFS of nodal up- and downstaging differed signifi-
cantly in both groups in univariable analyses (Figure 2).
Independent prognostic for 5-year DFS were pN stage (p¼ .007)
and lymph-angioinvasion (p¼ .019) in the surgery-alone group,
and cN metastases in the upper abdominal region (p¼ .049)
in the nCRT group (Table 3).
Discussion
Adequate clinical detection of LN metastases is a useful prog-
nostic indicator and essential in delineation of radiation tumor
volumes and extent of nodal dissection in EC [1]. In absence
of any reliable clinical assessment tool, the definitive diagnosis
Table 2. N-stage pattern in surgery-alone and nCRT group and regarding location of positive lymph nodes.
Equal nodal staging









All patients (N¼ 270)
Surgery alone (n¼135), n (%) 15 (11.1) 28 (20.7) 58 (43.0) 34 (25.2) <.001a
nCRT (n¼135), n (%) 22 (16.3) 16 (11.9) 22 (16.3) 75 (55.6)
Surgery-alone group (N¼ 135)
Adenocarcinoma (n¼ 115) 12 (10.4%) 25 (21.7%) 54 (47.0%) 24 (20.9%) .031b
Squamous cell
carcinoma (n¼ 20)
3 (15.0%) 3 (15.0%) 4 (20.0%) 10 (50.0%)
cT1/2 tumors (n¼ 21) 7 (33.3%) 4 (19.0%) 3 (14.3%) 7 (33.3%) .002b
cT3/4a tumors (n¼ 114) 8 (7.0%) 24 (21.1%) 55 (48.2%) 27 (23.7%)
nCRT group (N¼ 135)
Adenocarcinoma (n¼ 113) 17 (15.0%) 12 (10.6%) 22 (19.5%) 62 (54.9%) .026b
Squamous cell
carcinoma (n¼ 22)
5 (22.7%) 4 (18.2%) 0 (0.0%) 13 (59.1%)
cT1/2 tumors (n¼ 22) 8 (36.4%) 2 (9.1%) 1 (4.5%) 11 (50.0%) .037b
cT3/4a tumors (n¼ 113) 14 (12.4%) 14 (12.4%) 21 (18.6%) 64 (56.6%)
Patients with known lymph node locations (n¼ 146)
Upper mediastinal lymph nodes .022b
Surgery alone (n¼ 124) 102 (82.3%) 2 (1.6%) 5 (4.0%) 15 (12.1%)
nCRT (n¼ 122) 101 (82.8%) 0 (0.0%) 0 (0.0%) 21 (17.2%)
Lower mediastinal lymph nodes <.001a
Surgery alone (n¼ 124) 31 (25.0%) 41 (33.1%) 24 (19.4%) 28 (22.6%)
nCRT (n¼ 122) 46 (37.7%) 9 (7.4%) 11 (9.0%) 56 (45.9%)
Upper abdominal nodes <.001a
Surgery alone (n¼ 124) 52 (41.9%) 27 (21.8%) 35 (28.2%) 10 (8.1%)
nCRT (n¼ 122) 68 (55.7%) 6 (4.9%) 14 (11.5%) 34 (27.9%)
aChi-square test.
bLikelihood ratio.Surgery-alone versus nCRT group.
nCRT: neoadjuvant chemoradiotherapy; cN: clinical nodal stage; pN: pathological nodal stage; cT: clinical tumor stage.
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for pCR can only be made by pathologic examination of the
resected specimen . Even with current sophisticated diagnostic
methods, preoperative LN staging remains uncertain with con-
siderable high false negative rates [5,6]. In this study we found
a nodal downstaged ratio of 56% after nCRT, including a ‘true’
downstaging due to the neoadjuvant treatment and the so-
called ‘natural’ nodal downstaging through overestimation of
cN stage [25]. Surgery alone provided a nodal downstaging of
25%, indicating that a substantial part of the post-nCRT nodal
downstaging attributes to the inadequacy of pretreatment
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Figure 2. Kaplan–Meier curves for 5-year disease-free survival in nodal up- and downstaging in the surgery-alone and nCRT group. Disease-free survival in patients
treated with surgery alone (a) and patients treated with neoadjuvant chemoradiotherapy and surgery (b), with nodal upstaging and downstaging. Patients with
equal nodal clinical and pathological stage are not displayed. DFS: disease-free survival; nCRT: neoadjuvant chemoradiotherapy.
Table 3. Univariable and multivariable Cox regression analysis for 5-year disease-free survival in the surgery-alone and nCRT group.
Surgery-alone group nCRT group
HR 95% CI p value HR 95% CI p value
Univariable Cox regression analyses
Squamous cell carcinoma 0.78 0.38–1.56 .473 Squamous cell carcinoma 0.43 0.18–1.02 .054
cNþ upper/lower mediastinal 1.15 0.71–1.86 .583 cNþ upper/lower mediastinal 0.73 0.41–1.27 .263
cNþ upper abdominal 0.93 0.56–1.56 .791 cNþ upper abdominal& 2.38 1.36–4.16 .002
pT0 – – pT0 1.00 .095#
pT1&pT2 1.00 <.001# pT1&pT2 2.85 1.07–7.60 .036
pT3&pT4 2.82 1.51–5.27 pT3&pT4 2.71 1.04–7.08 .042
pN0 1.00 <.001# pN0& 1.00 .022#
pN1 3.46 1.62–7.37 <.001 pN1 1.28 0.62–2.67 .506
pN2 4.80 2.23 –10.30 <.001 pN2 3.38 1.19–9.64 .023
pN3 6.78 3.11–14.79 <.001 pN3 5.46 1.29–23.19 .021
pNþ upper/lower mediastinal& 2.71 1.65–4.44 <.001 pNþ upper/lower mediastinal& 2.10 1.07–4.11 .030
pNþ upper abdominal& 3.14 1.89–5.21 <.001 pNþ upper abdominal& 2.00 1.00–4.02 .051
Lymph-angioinvasion 2.64 1.63–4.29 <.001 Lymph-angioinvasion 1.67 0.90–3.11 .104
Lymph node ratio >0.2& 3.28 2.02–5.35 <.001 Lymph node ratio >0.2 6.57 2.51–17.22 <.001
R1-resection 3.54 1.78–7.04 <.001 R1-resection 4.81 1.68–13.82 .004
Equal nodal staging (cN¼ pN)& 1.00 <.001# Equal nodal staging (cN¼ pN) 1.00 .205
Nodal downstaging (cN> pN) 0.62 0.30–1.30 .204 Nodal downstaging (cN> pN) 0.75 0.40–1.44 .390
Nodal upstaging (cN< pN) 2.77 1.61–4.78 <.001 Nodal upstaging (cN< pN) 1.51 0.63–3.62 .350
Multivariable Cox regression analysis
Squamous cell carcinoma 0.74 0.29–1.90 .534
pT0 – – pT0 1.00 .268#
pT1&pT2 1.00 .080# pT1&pT2 2.38 0.84–6.76 .105
pT3&pT4 1.79 0.94–3.41 pT3&pT4 1.99 0.71–5.53 .189
pN0 1.00 .007# cNþ upper abdominal 1.85 1.00–3.40 .049
pN1 3.10 1.45–6.64 .004
pN2 3.46 1.56–7.67 .002
pN3 3.85 1.65–9.00 .002
Lymph-angioinvasion 1.87 1.11–3.15 .019 Lymph node ratio >0.2 2.84 0.67–12.10 .157
R1 resection 1.91 0.91–4.00 .087 R1 resection 1.82 0.41–8.18 .434
#Overall p-value of the categorical variables.Statistically significant (p< .05).
&These variables were not added to multivariable analyses to avoid multicollinearity.
nCRT: neoadjuvant chemoradiotherapy; HR: hazard ratio; CI: confidence interval; cNþ: positive clinical nodal stage; pT: pathological tumor stage; pCR: pathologic
complete response; pN: pathological nodal stage; pNþ: positive pathological nodal stage; R1: microscopic positive resection margin; cN: clinical nodal stage.
The bold values represent the statistically significant p values.
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staging rather than to treatment responses. This relative high
discordance in cN staging has a serious impact on prognosis
with a wide variation of pCR, hampering a proper selection of
patients who might benefit from a non-surgical wait-and-see
approach [26].
The nodal upstaging of 43% in the surgery-alone group is
comparable with the 44% in Crabtree study, despite they only
included T2 tumors [6]. However, the 16% upstaging in our
nCRT group was considerably lower than the 37% they
reported, probably because about 60% of their patients
received preoperative chemotherapy alone. Even with an
extensive staging, the accuracy of nodal staging was slightly
lower in our group (68 vs. 74%) [6]. Combined with an overes-
timated nodal involvement, as expressed by a 25% nodal
downstaging in the surgery-alone group, a substantial inaccur-
acy rate might be expected after nCRT. The downstaging
effect was even higher in cT1/T2 tumors (50%), but compar-
able to the nodal up and downstaging in cT3/T4 after nCRT,
suggesting a generally high nodal overstaging and probably
less CRT sensitivity in these advanced tumors. This potential
overestimation of response might contribute to the reported
large variety (25–42%) of complete responses [16,25,27].
Patients with pCR including a node-negative status
(ypT0N0), have a lower recurrence risk and higher survival.
While omission of surgery and a wait-and-see strategy have
been suggested, predicting prognosis in clinical complete
responders remains difficult, as ypT0N0 patients with nodal
downstaging (cNþ to ypN0) appeared to have a lower sur-
vival compared with true equal staged (cN0¼ ypN0) patients
[25,28]. This was also expressed in our study by a significant
better prognosis of patients with nodal downstaging than
those with nodal upstaging in both groups, probably due to
true nodal negative tumors (Figure 2).
Moreover, diagnostic inaccuracy has been indirectly
expressed by the fact that pN rather than cN stage has
found to be independent prognostic for overall survival [10].
Inferior survival in patients with ypN0 after nCRT versus
patients with pN0 after primary surgery was reported earlier,
suggesting a negative prognostic impact in case of sterilized
cNþ nodes (cNþ to ypN0) [29]. On the other hand, patients
with cN0 may benefit less from nCRT [30].
Interestingly, downstaging and pCR were more frequently
seen in patients with SCC compared to AC treated with nCRT
[16,31]. However, 50% nodal downstaging in SCC patients in
our surgery-alone group was considerably higher than the
reported 15% by Park et al. (Table 2) [32].
After propensity score matching, we found a higher
median number of resected LNs in the nCRT group com-
pared with the surgery-alone group (15 vs. 14 LNs, respect-
ively; Table 1). This is probably due to a slight difference in
the pathologic examination by introducing the intraoperative
marking of the radiation target volumes during surgery just
before the final esophagectomy, as nCRT was given from
2005 onwards. Moreover, the effect of nCRT on regression of
pathologic nodes particularly around the celiac axis may lead
to a higher resectability rate with a possible effect on the
number of resected nodes in these cases.
Nodal inaccuracy seemed to be T stage dependent in the
surgery-alone group (Table 2), expressed by a higher rate of
nodal upstaging in advanced tumor (T3/T4) stages. Others
also reported a disputable reliance of EUS in assessing
cNþwith even higher rates (80%) of overstaging in pN0
tumors [11,33]. In the surgery-alone group, nodal upstaging
was more common in the upper abdominal region (28%),
probably related to incomplete EUS staging by more severe
stenosis [34]. Since the presence of clinical abdominal LN
metastases in the upper abdominal region was independently
associated with DFS in the nCRT group, detection of these
metastases is important. Although EUS is the preferred
method to assess pathological abdominal LNs, PET-CT should
be performed in case of stenosis, since the accuracy of PET-CT
in detecting abdominal LNs is rather high [35]. Other possible
explanations for difficult nodal staging are the complexity of
longitudinal lymphatic drainage with skip metastases and
large number (>50%) of small LN metastases (<5mm) in EC
[32,36]. Improvement of PET-CT with diffusion-weighted mag-
netic resonance imaging (DWI-MRI) with gadofosveset might
increase the adequacy in detecting LN metastases, even in
small nodes [37]. Also promising is the elastography-enhanced
EUS measuring ultrasonic waves generated when light is
absorbed in the examined tissues with potential clinical use in
assessing regional LN involvement [38].
Certain limitations should be considered in interpreting
the results of this study. The integrated FDG-PET/CT was only
available after 2008, whereas CT followed by FDG-PET was
used between 2000 and 2009. The relatively long inclusion
period (2000–2015) could have a possible effect on the
accuracy of staging, using the next generation of staging
techniques over time in the nCRT group, as these patients
were diagnosed after 2005. Next, the accuracy of EUS might
be higher if FNA could be applied to more distinct LNs,
whereas it was performed selectively in clinically suspected
LNs considered as relevant in determining the extent of radi-
ation fields and/or nodal resection. Moreover, these data
were based on a single institution rather than a desirable
multicenter study.
In conclusion, nodal up- and downstaging (43 and 25%)
are frequently found in EC patients after surgery alone and
more often in upper abdominal and lower mediastinal LNs,
respectively. The observed discordancy with a substantial
overstaging (cN>pN) and inaccuracy in cN staging in the
primary surgery group has an impact on the prognostic
strength of ypN after nCRT. Improvement of current pre-
operative nodal staging in assessing the genuine effect of
nCRT is important to optimize future individualized treat-
ment options, including the feasibility of a wait-and-see
approach in clinical complete responders.
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